MedicaidPrior AuthMedium impact
Prior Authorization of Lipotropics, Other - Pharmacy Services MAB 01-16-24
Pennsylvania Medicaid (DHS)·PA · Cardiology, Endocrinology, Family Medicine +2 more·Prior Authorization
Effective date
Jul 11, 2016
We identified it
Jun 20, 2026
Summary
Pennsylvania Medicaid has updated prior authorization requirements for lipotropic medications (cholesterol-lowering drugs), removing specific guidelines for Zetia since it's now preferred. The policy establishes detailed medical necessity criteria for non-preferred lipotropics, PCSK9 inhibitors, and other cholesterol medications requiring prior authorization.
Action Required
By July 11, 2016: Billing team must update prior authorization procedures for Pennsylvania Medicaid patients receiving lipotropic medications. Remove Zetia from prior authorization requirements since it's now preferred. Ensure prescribers follow updated medical necessity documentation requirements for non-preferred lipotropics, PCSK9 inhibitors (like Repatha, Praluent), and specialty medications like Kynamro and Juxtapid. Verify specialist consultation requirements are met for complex cases. Claims for non-preferred lipotropics without proper prior authorization will be denied.